NCT01386515 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Branstetter JE, Domian EW, Williams PD, Graff JC, Piamjariyakul U
Communication themes in families of children with chronic conditions. Issues Compr Pediatr Nurs. 2008 Oct-Dec;31(4):171-84. doi: 10.1080/01460860802475184.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010 Feb;9(2):177-89. doi: 10.1016/S1474-4422(09)70272-8. Epub 2009 Nov 27. Review. Erratum in: Lancet Neurol. 2010 Mar;9(3):237.
Chen JY, Clark MJ
Family function in families of children with Duchenne muscular dystrophy. Fam Community Health. 2007 Oct-Dec;30(4):296-304.

The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)

Clinical trial NCT01386515 - References